反应详情

Prepared according to procedure Y using 4-chloro-2-(3,5-difluorophenyl)-3-methyl-1,8-naphthyridine (68 mg, 0.234 mmol), 4-(3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-6-yl)morpholine (54.6 mg, 0.234 mmol), sodium tert-butoxide (45 mg, 0.468 mmol) and XPhos precatalyst (17.1 mg, 0.023 mmol) in toluene (4 mL) for 2 hours at 110° C. Purification by reverse phase HPLC (10 to 60% acetonitrile in waiter) gave 2-(3,5-difluorophenyl)-4-(3,3-dimethyl-6-(4-morpholinyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)-3-methyl-1,8-naphthyridine. 1H NMR (400 MHz, chloroform-d) δ ppm 9.13 (1H, dd, J=4.3, 2.0 Hz), 8.17 (1H, dd, J=8.2, 2.0 Hz), 7.65 (1H, d, J=2.3 Hz), 7.45 (1H, dd, J=8.3, 4.2 Hz), 7.25-7.28 (2H, m), 6.91-6.98 (1H, m), 5.78 (1H, d, J=2.5 Hz), 3.86-3.91 (1H, m), 3.79-3.84 (1H, m), 3.71-3.78 (4H, m), 2.94-3.04 (4H, m), 2.37 (3H, s), 1.58 (3H, s), 1.53 (3H, s). Mass Spectrum (ESI) m/e=488.2 (M+1).

1. customPrepared
2. customfor 2 hours
3. customat 110° C
4. customPurification by reverse phase HPLC (10 to 60% acetonitrile in waiter)